BioStock: Alzinova takes the next step towards a phase II study in the US

Alzinova has taken a significant step towards starting its planned phase II study with ALZ-101 by submitting a Clinical Trial Application (IND) to the US Food and Drug Administration (FDA). At the same time, the company has applied for Fast Track designation, which can accelerate the development of the therapeutic vaccine against Alzheimer’s disease. We contacted CEO Tord Labuda for a comment.

Read the full interview with Tord Labuda at biostock.se:

https://biostock.se/en/2025/08/alzinova-takes-the-next-step-towards-a-phase-ii-study-in-the-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/